Insulin Resistance Increases the Occurrence of New Cardiovascular Events in Patients with Manifest Arterial Disease Without Known Diabetes. the SMART Study

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2011 Nov 22

PMID 22098712

Citations 16

Authors

Sandra N Verhagen

Annemarie M J Wassink

Yolanda van der Graaf

Petra M Gorter

Frank L J Visseren

Affiliations

Soon will be listed here.

Abstract

Background: Insulin resistance is accompanied by a cluster of metabolic changes, often referred to as metabolic syndrome. Metabolic syndrome is associated with an increased cardiovascular risk in patients with manifest arterial disease. We investigated whether insulin resistance is associated with an increased risk for cardiovascular events in patients with manifest arterial disease without known diabetes and whether this can be explained by the components of the metabolic syndrome or by inflammation.

Methods: Prospective cohort study in 2611 patients with manifest arterial disease without known diabetes. Homeostasis model of insulin resistance (HOMA-IR) was used to quantify insulin resistance. The relation of HOMA-IR with cardiovascular events (vascular death, myocardial infarction or stroke) and all cause mortality was assessed with Cox regression analysis. In additional models adjustments were performed for the single components constituting the metabolic syndrome and for inflammation.

Results: HOMA-IR increases with the number of metabolic syndrome components (mean HOMA-IR ± SD in groups with 0, 1, 2, 3, 4 and 5 metabolic syndrome components: 1.4 ± 0.7; 1.8 ± 1.2; 2.4 ± 1.5; 3.1 ± 1.8; 4.0 ± 2.6; and 5.6 ± 3.6 respectively). High HOMA-IR was independently associated with an increased risk of cardiovascular events (tertile 2 vs. 1 HR 1.92; 95%CI 1.20-3.08) (tertile 3 vs.1 HR 1.78; 95%CI 1.10-2.89) and with all cause mortality (tertile 2 vs. 1 HR 1.80; 95%CI 1.04-3.10) (tertile 3 vs.1 HR 1.56; 95%CI 0.88-2.75). These relations were not influenced by the individual components of metabolic syndrome or by inflammation.

Conclusions: In patients with manifest arterial disease without known diabetes, insulin resistance increases with the number of metabolic syndrome components, and elevated insulin resistance increases the risk of new cardiovascular events.

Citing Articles

Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors.

Bratt G, Brannstrom J, Missalidis C, Nystrom T PLoS One. 2021; 16(6):e0254079.

PMID: 34191847 PMC: 8244855. DOI: 10.1371/journal.pone.0254079.

Target Elimination-Denatured and Unstable Proteins, Environmental Toxins, Metabolic Wastes, Immunosuppressive Factors and Chronic Inflammatory Factors of Medical System for Chronic Diseases Prevention and Health Promotion: A Narrative Review.

Zhang J, Jiang Z, Wei W, Li X, Sun C, Zhang Y Iran J Public Health. 2019; 48(6):994-1003.

PMID: 31341840 PMC: 6635331.

Lifestyle modification interventions differing in intensity and dietary stringency improve insulin resistance through changes in lipoprotein profiles.

Ellsworth D, Costantino N, Blackburn H, Engler R, Kashani M, Vernalis M Obes Sci Pract. 2016; 2(3):282-292.

PMID: 27708845 PMC: 5043634. DOI: 10.1002/osp4.54.

Association between alpha-fetoprotein and metabolic syndrome in a Chinese asymptomatic population: a cross-sectional study.

Chen Y, Zhao Y, Feng L, Zhang J, Zhang J, Feng G Lipids Health Dis. 2016; 15:85.

PMID: 27121855 PMC: 4848775. DOI: 10.1186/s12944-016-0256-x.

Chronic stress, inflammation, and glucose regulation in U.S. Hispanics from the HCHS/SOL Sociocultural Ancillary Study.

McCurley J, Mills P, Roesch S, Carnethon M, Giacinto R, Isasi C Psychophysiology. 2015; 52(8):1071-9.

PMID: 25898909 PMC: 4640890. DOI: 10.1111/psyp.12430.

References

Bonora E, Targher G, Alberiche M, Bonadonna R, Saggiani F, Zenere M . Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23(1):57-63. DOI: 10.2337/diacare.23.1.57. View

Khan A, Cheng S, Magnusson M, Larson M, Newton-Cheh C, McCabe E . Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011; 96(10):3242-9. PMC: 3200240. DOI: 10.1210/jc.2011-1182. View

Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L . Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med. 2002; 19(6):470-5. DOI: 10.1046/j.1464-5491.2002.00719.x. View

Gomez-Marcos M, Recio-Rodriguez J, Patino-Alonso M, Agudo-Conde C, Gomez-Sanchez L, Rodriguez-Sanchez E . Relationship between intima-media thickness of the common carotid artery and arterial stiffness in subjects with and without type 2 diabetes: a case-series report. Cardiovasc Diabetol. 2011; 10:3. PMC: 3034668. DOI: 10.1186/1475-2840-10-3. View

Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-89. DOI: 10.1016/S0140-6736(05)67528-9. View

Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs J . Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007; 30(2):318-24. DOI: 10.2337/dc06-0919. View

Saely C, Aczel S, Marte T, Langer P, Hoefle G, Drexel H . The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab. 2005; 90(10):5698-703. DOI: 10.1210/jc.2005-0799. View

Scuteri A, Najjar S, Muller D, Andres R, Hougaku H, Metter E . Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004; 43(8):1388-95. DOI: 10.1016/j.jacc.2003.10.061. View

Sakkinen P, Wahl P, Cushman M, Lewis M, Tracy R . Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000; 152(10):897-907. DOI: 10.1093/aje/152.10.897. View

10.

Kim J, Montagnani M, Kon Koh K, Quon M . Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113(15):1888-904. DOI: 10.1161/CIRCULATIONAHA.105.563213. View

11.

Frye R, August P, Brooks M, Hardison R, Kelsey S, MacGregor J . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24):2503-15. PMC: 2863990. DOI: 10.1056/NEJMoa0805796. View

12.

van de Woestijne A, Monajemi H, Kalkhoven E, Visseren F . Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev. 2011; 12(10):829-40. DOI: 10.1111/j.1467-789X.2011.00900.x. View

13.

Wassink A, van der Graaf Y, Olijhoek J, Visseren F . Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2008; 29(2):213-23. DOI: 10.1093/eurheartj/ehm582. View

14.

Wheatcroft S, Williams I, Shah A, Kearney M . Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003; 20(4):255-68. DOI: 10.1046/j.1464-5491.2003.00869.x. View

15.

Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G . Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes. 1988; 37(6):780-6. DOI: 10.2337/diab.37.6.780. View

16.

Meigs J, Rutter M, Sullivan L, Fox C, DAgostino Sr R, Wilson P . Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007; 30(5):1219-25. DOI: 10.2337/dc06-2484. View

17.

Tenenbaum A, Fisman E . "The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol. 2011; 10:11. PMC: 3036609. DOI: 10.1186/1475-2840-10-11. View

18.

Haffner S, Miettinen H, Stern M . The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997; 20(7):1087-92. DOI: 10.2337/diacare.20.7.1087. View

19.

Hanley A, Williams K, Stern M, Haffner S . Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002; 25(7):1177-84. DOI: 10.2337/diacare.25.7.1177. View

20.

Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L . HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002; 25(7):1135-41. DOI: 10.2337/diacare.25.7.1135. View